These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 15828219)

  • 1. [PPARs as molecular targets for drug discovery].
    Kagechika H; Miyachi H
    Nihon Rinsho; 2005 Apr; 63(4):549-55. PubMed ID: 15828219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
    Michalik L; Auwerx J; Berger JP; Chatterjee VK; Glass CK; Gonzalez FJ; Grimaldi PA; Kadowaki T; Lazar MA; O'Rahilly S; Palmer CN; Plutzky J; Reddy JK; Spiegelman BM; Staels B; Wahli W
    Pharmacol Rev; 2006 Dec; 58(4):726-41. PubMed ID: 17132851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins.
    Schachtrup C; Emmler T; Bleck B; Sandqvist A; Spener F
    Biochem J; 2004 Aug; 382(Pt 1):239-45. PubMed ID: 15130092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptors as attractive antiobesity targets.
    Zhang F; Lavan B; Gregoire FM
    Drug News Perspect; 2004 Dec; 17(10):661-9. PubMed ID: 15696231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors and inflammation.
    Moraes LA; Piqueras L; Bishop-Bailey D
    Pharmacol Ther; 2006 Jun; 110(3):371-85. PubMed ID: 16168490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    Am J Clin Dermatol; 2008; 9(1):15-31. PubMed ID: 18092840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
    Kim MJ; Deplewski D; Ciletti N; Michel S; Reichert U; Rosenfield RL
    Mol Genet Metab; 2001 Nov; 74(3):362-9. PubMed ID: 11708867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
    Guan Y
    Minerva Urol Nefrol; 2002 Jun; 54(2):65-79. PubMed ID: 12185990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety issues and prospects for future generations of PPAR modulators.
    Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
    Guan Y; Breyer MD
    Kidney Int; 2001 Jul; 60(1):14-30. PubMed ID: 11422732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.
    Merk D; Lamers C; Weber J; Flesch D; Gabler M; Proschak E; Schubert-Zsilavecz M
    Bioorg Med Chem; 2015 Feb; 23(3):499-514. PubMed ID: 25583100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.
    Crowe DL; Chandraratna RA
    Breast Cancer Res; 2004; 6(5):R546-55. PubMed ID: 15318936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological and therapeutic roles of peroxisome proliferator-activated receptors.
    Berger J; Wagner JA
    Diabetes Technol Ther; 2002; 4(2):163-74. PubMed ID: 12079620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
    Tan CK; Zhuang Y; Wahli W
    Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.